<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-id journal-id-type="iso-abbrev">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3952475</article-id><article-id pub-id-type="publisher-id">cc12926</article-id><article-id pub-id-type="doi">10.1186/cc12926</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Rapid molecular test (SeptiFast<sup>&#x000ae;</sup>) reduced time for adjustment of antibiotic treatment in comparison with conventional blood cultures in critically ill sepsis patients: a randomized controlled clinical trial (preliminary results)</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Rodrigues</surname><given-names>Cristhieni</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>dos Santos</surname><given-names>Mirlane Silva</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Filho</surname><given-names>Helio Hehl Caiaffa</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Charbel</surname><given-names>Cecilia Eug&#x000ea;nia</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>da Silva</surname><given-names>Luciane de Carvalho Sarahyba</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Rossi</surname><given-names>Fl&#x000e1;via</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Franco</surname><given-names>Maria Renata Gomes</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Siciliano</surname><given-names>Rinaldo Focaccia</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Strabelli</surname><given-names>T&#x000e2;nia Mara Varej&#x000e3;o</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Infection Control Unit, Heart Institute (InCor), University of Sao Paulo Medical School, Sao Paulo, Brazil</aff><aff id="I2"><label>2</label>Molecular Biology Branch, Central Laboratory Division, University of Sao Paulo Medical School, Sao Paulo, Brazil</aff><aff id="I3"><label>3</label>Central Laboratory Division, University of Sao Paulo Medical School, Sao Paulo, Brazil</aff><pub-date pub-type="ppub"><year>2013</year></pub-date><pub-date pub-type="epub"><day>5</day><month>11</month><year>2013</year></pub-date><volume>17</volume><issue>Suppl 4</issue><supplement><named-content content-type="supplement-title">Sepsis 2013</named-content><named-content content-type="supplement-sponsor">Publication of this supplement was funded by the conference.</named-content></supplement><fpage>P26</fpage><lpage>P26</lpage><permissions><copyright-statement>Copyright &#x000a9; 2013 Rodrigues et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Rodrigues et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://ccforum.com/content/17/S4/P26"/><conference><conf-date>5-6 November 2013</conf-date><conf-name>Sepsis 2013</conf-name><conf-loc>Rio de Janeiro, Brazil</conf-loc></conference></article-meta></front><body><sec><title>Background</title><p>Sepsis is the main cause of death in ICUs all over the world. Early detection of the pathogen is essential for appropriate antimicrobial treatment.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>To evaluate the reduction in time of antimicrobial adjustment therapy in patients with sepsis comparing a rapid molecular test (SeptiFast<sup>&#x000ae;</sup>) with conventional blood cultures, a randomized controlled clinical trial was conducted between October 2012 and May 2013 in a cardiology hospital. Adult patients staying more than 48 hours in hospital with clinical suspicion of sepsis were included in the study. Blood samples were collected for cultures (BacT/ALERT<sup>&#x000ae;</sup>) and Septifast<sup>&#x000ae; </sup>test immediately prior to initiation of antibiotic therapy. Patients were allocated into two groups. In the Intervention Group (GI), Septifast<sup>&#x000ae; </sup>results were communicated to the medical researcher and antimicrobials were adjusted. In the Control Group (GII), Septifast<sup>&#x000ae; </sup>results were not informed and therapy adjustment was based on the blood culture. Registered in Clinical trials.gov (NCT 01450358).</p></sec><sec sec-type="results"><title>Results</title><p>Forty-six patients were included, 17 in GI and 29 in GII. Key data are shown in Table <xref ref-type="table" rid="T1">1</xref>. In GI therapy adjustment was done in 580 minutes compared with 3,007 minutes in GII (<italic>P </italic>= 0.004).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Distribution of characteristics in the two groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="left">Intervention group (<italic>n</italic>= 17)</th><th align="left">Control group (<italic>n</italic>= 29)</th><th align="left"><italic>P </italic>value</th></tr></thead><tbody><tr><td align="left">Age (years)</td><td align="left">63 (46 to 75)</td><td align="left">66 (39 to 85)</td><td align="left">0.340</td></tr><tr><td align="left">Gender (female)</td><td align="left">5 (30%)</td><td align="left">10 (34%)</td><td align="left">0.999</td></tr><tr><td align="left">Hospital stay (mean, days)</td><td align="left">32 (9 to 118)</td><td align="left">31 (3 to 112)</td><td align="left">0.632</td></tr><tr><td align="left">APACHE II (mean)</td><td align="left">17 (8 to 29)</td><td align="left">17 (8 to 29)</td><td align="left">0.730</td></tr><tr><td align="left">Ejection fraction &#x0003c;40%</td><td align="left">8 (47%)</td><td align="left">17 (58%)</td><td align="left">0.545</td></tr><tr><td align="left">Receiving antibiotics prior to study</td><td align="left">11 (65%)</td><td align="left">11 (38%)</td><td align="left">0.126</td></tr><tr><td align="left">Septic shock</td><td align="left">9 (53%)</td><td align="left">16 (55%)</td><td align="left">0.999</td></tr><tr><td align="left">Patients with adjustment therapy based on SeptiFast<sup>&#x000ae;</sup></td><td align="left">6 (35%)</td><td align="left">-</td><td/></tr><tr><td align="left">Patients with adjustment therapy based on blood culture</td><td align="left">-</td><td align="left">7 (21%)</td><td/></tr><tr><td align="left">Mean time (minutes) of adjustment therapy</td><td align="left">580</td><td align="left">3,007</td><td align="left">0.004</td></tr><tr><td align="left">Pathogens detected in SeptiFast<sup>&#x000ae;</sup></td><td align="left"><italic>P. aeruginosa </italic>(2), <italic>K. pneumonia/oxytoca </italic>(1), <italic>E. aerogenes/cloacae </italic>(1), <italic>S. marcescens </italic>(1), <italic>A. baumanii </italic>(1)</td><td align="left">-</td><td/></tr><tr><td align="left">Pathogens detected in blood culture</td><td align="left">-</td><td align="left"><italic>S. aureus </italic>(4), <italic>K. pneumonia </italic>(2), <italic>M. morganii </italic>(1)</td><td/></tr><tr><td align="left">28-day mortality</td><td align="left">9 (53%)</td><td align="left">17 (59%)</td><td align="left">0.765</td></tr></tbody></table></table-wrap></sec><sec sec-type="conclusions"><title>Conclusions</title><p>The rapid molecular test (SeptiFast<sup>&#x000ae;</sup>) reduced the time for adjustment of antibiotic treatment in comparison with conventional blood cultures in critically ill sepsis patients.</p></sec></body></article>